Key result
Higher serum alpha-Klotho linked to ~48% lower odds of severe CAD on CCTA.
Why the study?
Alpha-Klotho has anti-aging and vasculoprotective properties that may influence vascular calcification, but its link to coronary atherosclerotic burden and cardiometabolic risk indices required investigation.
Are lower serum alpha-Klotho levels associated with greater coronary atherosclerotic burden in patients undergoing coronary CT angiography?
Cross-Sectional (n=86)
No
Are lower serum alpha-Klotho levels associated with greater coronary atherosclerotic burden in patients undergoing coronary CT angiography?
Odds Ratio: 0.525 (95% CI 0.29–0.949)
p-value: p=0.033
Lower serum alpha-Klotho levels are independently associated with greater coronary atherosclerotic burden, suggesting its potential as a circulating biomarker for coronary atherosclerosis.
May support alpha-Klotho as a biomarker candidate; leaves open its clinical utility pending prospective validation.
Background/Objectives: Alpha-Klotho is a circulating protein with anti-aging and vasculoprotective properties that may play a role in vascular calcification. This study aimed to investigate the association between serum alpha-Klotho levels and coronary atherosclerotic burden assessed by the Agatston score and CAD-RADS grading, as well as cardiometabolic risk indices. Methods: This single-center, prospective, cross-sectional study included 86 patients undergoing coronary computed tomography angiography. Serum alpha-Klotho levels were measured by ELISA. Associations with imaging and metabolic variables were assessed using Spearman correlation and age-adjusted partial correlation analyses. Independent associations were evaluated using multivariable linear regression with HC3-robust standard errors. Binary and ordinal logistic regression models with CAD-RADS as the dependent variable and receiver operating characteristic (ROC) analysis were additionally performed. Results: Serum Klotho levels were negatively correlated with age (ρ = −0.598), Agatston score (ρ = −0.540), and CAD-RADS (ρ = −0.549) (all p < 0.001). Associations with the Agatston score and CAD-RADS remained significant after age adjustment (ρ = −0.348 and −0.352, respectively). AIP also remained independently associated with Klotho after age adjustment (ρ = −0.289, p = 0.007), whereas associations with TyG and METS-IR were attenuated. Multivariable models explained 50–52% of the variance in Klotho. In ordinal logistic regression, Klotho remained independently associated with CAD-RADS severity after adjustment for age, sex, BMI, and AIP (OR = 0.525, p = 0.033). ROC analysis demonstrated moderate discrimination for the presence of coronary atherosclerosis, defined as Agatston score > 0 (equivalently, CAD-RADS > 0 in this cohort) (AUC = 0.754, 95% CI 0.654–0.855); an exploratory, internally derived cutoff of ≤823 pg/mL—not a clinically validated threshold—yielded 72.0% sensitivity and 75.0% specificity (bootstrap-validated optimism-corrected: 69.3% and 72.5%). Conclusions: Lower serum alpha-Klotho levels were independently associated with greater coronary atherosclerotic burden and showed moderate discriminative ability for its presence. These findings are preliminary and support further investigation of alpha-Klotho as a candidate circulating biomarker of coronary atherosclerosis, pending validation in larger, prospective cohorts.
No takes yet. Share an insight, caveat, or question.
Tuzcu et al. (2026) conducted a cross-sectional in Coronary atherosclerosis (n=86). Serum alpha-Klotho levels was evaluated on CAD-RADS severity (ordinal scale 0-5) (OR 0.525, 95% CI 0.290-0.949, p=0.033). Lower serum alpha-Klotho levels were independently associated with greater coronary atherosclerotic severity on CCTA (OR 0.525, 95% CI 0.290-0.949, p=0.033).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: